Cargando…
The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index
Background: This study aimed to analyze the clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease (COPD) with low body mass index (BMI). Methods: In this cross-sectional study, we enrolled patients with stable COPD from the database setup by the Secon...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372446/ https://www.ncbi.nlm.nih.gov/pubmed/37521460 http://dx.doi.org/10.3389/fphar.2023.1131614 |
_version_ | 1785078379225022464 |
---|---|
author | Song, Qing Zhou, Aiyuan Lin, Ling Li, Xueshan Cheng, Wei Liu, Cong Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping |
author_facet | Song, Qing Zhou, Aiyuan Lin, Ling Li, Xueshan Cheng, Wei Liu, Cong Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping |
author_sort | Song, Qing |
collection | PubMed |
description | Background: This study aimed to analyze the clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease (COPD) with low body mass index (BMI). Methods: In this cross-sectional study, we enrolled patients with stable COPD from the database setup by the Second Xiangya Hospital of Central South University. We classified the patients into three groups based on BMI: low-BMI (<18.5 kg/m(2)), normal-BMI (≥18.5 and <24.0 kg/m(2)), and high-BMI (≥24 kg/m(2)) groups. We defined clinically important deterioration (CID) as a COPD Assessment Test (CAT) score increase of ≥2 and minimum clinically important difference (MCID) as a CAT score decrease of ≥2 during 6 months of follow-up. We recorded the number of exacerbations and mortality during 1 year of follow-up. Results: A total of 910 COPD patients were included with 144 (15.8%) patients in low-BMI, 475 (52.2%) in normal-BMI, and 291 (32.0%) in high-BMI groups. Patients with low BMI had worse pulmonary function, higher symptom scores, and exacerbations in the past year compared with normal- and high-BMI groups (p < 0.05). Logistic regression analysis revealed that age, Global Initiative for Chronic Obstructive Lung Disease grades 3 and 4, and hospitalizations in the past year were independent risk factors for patients with low BMI (p < 0.05). After 1 year of follow-up, patients with low BMI had higher mortality and number of hospitalizations. Patients with low BMI were more likely to attain CID and less likely to attain MCID compared with patients with high BMI (p < 0.05). In addition, patients with low BMI treated with long-acting β2-agonist (LABA)+long-acting muscarinic antagonist (LAMA) and LABA+LAMA+inhaled corticosteroid (ICS) were more likely to attain MCID than those treated with LABA+ICS and LAMA (p < 0.05). Conclusion: COPD patients with low BMI had worse pulmonary function, higher symptom scores, and higher risk of future hospitalizations and mortality and were less likely to attain MCID and more likely to attain CID. It is worth noting that patients with low BMI treated with LABA+LAMA and LABA+LAMA+ICS were more likely to attain MCID than those treated with LABA+ICS and LAMA. |
format | Online Article Text |
id | pubmed-10372446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103724462023-07-28 The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index Song, Qing Zhou, Aiyuan Lin, Ling Li, Xueshan Cheng, Wei Liu, Cong Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping Front Pharmacol Pharmacology Background: This study aimed to analyze the clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease (COPD) with low body mass index (BMI). Methods: In this cross-sectional study, we enrolled patients with stable COPD from the database setup by the Second Xiangya Hospital of Central South University. We classified the patients into three groups based on BMI: low-BMI (<18.5 kg/m(2)), normal-BMI (≥18.5 and <24.0 kg/m(2)), and high-BMI (≥24 kg/m(2)) groups. We defined clinically important deterioration (CID) as a COPD Assessment Test (CAT) score increase of ≥2 and minimum clinically important difference (MCID) as a CAT score decrease of ≥2 during 6 months of follow-up. We recorded the number of exacerbations and mortality during 1 year of follow-up. Results: A total of 910 COPD patients were included with 144 (15.8%) patients in low-BMI, 475 (52.2%) in normal-BMI, and 291 (32.0%) in high-BMI groups. Patients with low BMI had worse pulmonary function, higher symptom scores, and exacerbations in the past year compared with normal- and high-BMI groups (p < 0.05). Logistic regression analysis revealed that age, Global Initiative for Chronic Obstructive Lung Disease grades 3 and 4, and hospitalizations in the past year were independent risk factors for patients with low BMI (p < 0.05). After 1 year of follow-up, patients with low BMI had higher mortality and number of hospitalizations. Patients with low BMI were more likely to attain CID and less likely to attain MCID compared with patients with high BMI (p < 0.05). In addition, patients with low BMI treated with long-acting β2-agonist (LABA)+long-acting muscarinic antagonist (LAMA) and LABA+LAMA+inhaled corticosteroid (ICS) were more likely to attain MCID than those treated with LABA+ICS and LAMA (p < 0.05). Conclusion: COPD patients with low BMI had worse pulmonary function, higher symptom scores, and higher risk of future hospitalizations and mortality and were less likely to attain MCID and more likely to attain CID. It is worth noting that patients with low BMI treated with LABA+LAMA and LABA+LAMA+ICS were more likely to attain MCID than those treated with LABA+ICS and LAMA. Frontiers Media S.A. 2023-07-13 /pmc/articles/PMC10372446/ /pubmed/37521460 http://dx.doi.org/10.3389/fphar.2023.1131614 Text en Copyright © 2023 Song, Zhou, Lin, Li, Cheng, Liu, Peng, Zeng, Yi, Liu, Li, Chen, Cai and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Song, Qing Zhou, Aiyuan Lin, Ling Li, Xueshan Cheng, Wei Liu, Cong Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
title | The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
title_full | The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
title_fullStr | The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
title_full_unstemmed | The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
title_short | The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
title_sort | clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372446/ https://www.ncbi.nlm.nih.gov/pubmed/37521460 http://dx.doi.org/10.3389/fphar.2023.1131614 |
work_keys_str_mv | AT songqing theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT zhouaiyuan theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT linling theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT lixueshan theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT chengwei theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT liucong theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT pengyating theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT zengyuqin theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT yirong theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT liuyi theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT lixin theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT chenyan theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT caishan theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT chenping theclinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT songqing clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT zhouaiyuan clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT linling clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT lixueshan clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT chengwei clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT liucong clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT pengyating clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT zengyuqin clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT yirong clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT liuyi clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT lixin clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT chenyan clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT caishan clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex AT chenping clinicalcharacteristicsandtreatmentresponseofpatientswithchronicobstructivepulmonarydiseasewithlowbodymassindex |